Previous 10 | Next 10 |
2023-04-20 16:24:00 ET Shares of Prometheus Biosciences (NASDAQ: RXDX) were skyrocketing 70% higher this week, as of the market close on Thursday, according to data provided by S&P Global Market Intelligence . The huge gain came after Merck (NYSE: MRK) annou...
2023-04-19 10:45:00 ET Earlier this week, Merck (NYSE: MRK) went shopping and purchased the precision-medicine company Prometheus Biosciences (NASDAQ: RXDX) for $200 a share, for a total value of $10.8 billion. The transaction is expected to close in the third quarter of...
NEW YORK, NY / ACCESSWIRE / April 18, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Prometheus Biosciences, Inc. (NASDAQ...
2023-04-18 08:45:06 ET Palm Beach, FL – April 18, 2023 – FinancialNewsMedia.com News Commentary – Alcohol consumption and drug abuse have become public health concerns worldwide. Governments are working on ways to detect any symptoms of alcohol consumpt...
2023-04-18 01:41:44 ET Summary Morphic Holding is developing innovative oral integrin therapies with lead candidate MORF-057 in phase 2. MORF-057 targets α4β7, a highly validated mechanism of action similar to Entyvio, which generated ~4$Bn in sales during 2021. ...
2023-04-17 17:50:10 ET Stocks notched modest gains in choppy action on Monday. The major averages bounced around the unchanged mark for most of the day, before drifting higher in the final hours of the session. M&A headlines prompted gains in a couple of select names. Prometheus Bio...
2023-04-17 13:55:29 ET Biopharmaceutical stocks were trending higher across the board Monday morning, thanks to Merck 's (NYSE: MRK) nearly $11 billion buyout offer for Prometheus Biosciences (NASDAQ: RXDX) . So far, some of the day's biggest winners have been the cancer...
2023-04-17 12:09:30 ET Shares of Prometheus Biosciences (NASDAQ: RXDX) were up more than 69% Monday morning after Merck (NYSE: MRK) said Sunday that it had come to an agreement to buy the clinical-stage biotech for $10.8 billion. Prometheus focuses on therapies to t...
2023-04-17 10:56:01 ET Prometheus Biosciences Inc ( NASDAQ: RXDX ) opened about 70% up on Monday after Merck & Co Inc ( NYSE: MRK ) said it will buy the biotechnology company for $10.8 billion. What’s in it for Merck & Co? The all-cash agreement values eac...
2023-04-17 10:02:16 ET Gainers: Prometheus Biosciences ( RXDX ) +69% . CNS Pharmaceuticals ( CNSP ) +53% . Revelation Biosciences ( REVB ) +29% . Windtree Therapeutics ( WINT ) +26% . Kiromic BioPharma ( KRBP ) +22% . Loser...
News, Short Squeeze, Breakout and More Instantly...
Prometheus Biosciences Inc. Company Name:
RXDX Stock Symbol:
NASDAQ Market:
Prometheus Biosciences Inc. Website:
NEW YORK, NY / ACCESSWIRE / May 25, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Prometheus Biosciences, Inc. (NASDAQ:RXDX...
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated disease...